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Rationale: Pigment epithelium-derived factor (PEDF) is a 50 kD small secreting glycoprotein 
that participates in multiple physiological and pathological processes. Recent studies have 
reported that PEDF plays an important role in inflammatory responses in several diseases. 
However, the role of PEDF in the pathogenesis of chronic obstructive pulmonary disease 
(COPD) remains unclear.
Objective: The aim of the present study is to explore the potential relationship between PEDF 
and COPD.
Methods: We used differential proteomics – stable isotope labeling with amino acids in cell 
culture – to investigate protein expression profile changes in cigarette smoke extract-treated 
pulmonary cells and found that the neurotrophic and antiangiogenic protein PEDF was abnor-
mally expressed. Furthermore, Western blotting was used to detect the expression of PEDF in 
the lung tissue of rats that were exposed to cigarette smoke. Eighty subjects between the ages of 
40–90 years, including 20 healthy nonsmokers, ten smoking volunteers, and 50 COPD patients, 
were recruited from September 2012 until August 2013 in Sichuan Province, People’s Republic 
of China. We measured the plasma PEDF concentration and classic proinflammatory cytokines 
by multiplex enzyme-linked immunosorbent assay. In addition, we performed a spirometry 
examination to diagnose COPD patients and we also analyzed the correlation between PEDF 
and lung function.
Results: First, we found that the expression of PEDF in cigarette smoke extract-treated cells 
increased 16.2-fold when compared with the control group. Next, we confirmed that 4 weeks’ 
exposure to cigarette smoke can upregulate PEDF levels in rat lung tissues. We also discovered 
that plasma PEDF in COPD patients was significantly increased when compared with either 
healthy nonsmoking or smoking subjects. Furthermore, circulating PEDF was correlated with 
inflammatory cytokine and blood neutrophil numbers, but it was reversely associated with a 
decline in forced expiratory volume in 1 second percent predicted.
Conclusion: Our findings provide a novel link between PEDF and COPD. Elevated PEDF 
levels may be involved in promoting the development of COPD by performing proinflamma-
tory functions.
Keywords: chronic obstructive pulmonary disease, pigment epithelium-derived factor, cigarette 
smoke, inflammation
Introduction
Chronic obstructive pulmonary disease (COPD) is a disease characterized by 
progressive airflow limitations that are poorly reversible and closely associated 
with aberrant inflammatory responses to noxious particles.1 Recent research has 
found in both pulmonary and systemic circulation in COPD patients the release of 
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proinflammatory cytokines, which are considered to play 
significant roles in the pathogenesis of COPD.2,3
Pigment epithelium-derived factor (PEDF) is a 50 kD 
small secreting glycoprotein that belongs to a noninhibitory 
serpin family group. PEDF was first identified as a potent 
angiostatic cytokine that originated from human retinal pig-
ment epithelium.4 Several other observations showed that 
PEDF is also expressed in many tissues, such as adipose 
and lung tissues.5,6 PEDF participates in multiple physio-
logical and pathological processes.7,8 It has been reported 
that PEDF is a potent endogenous molecule that induces 
tumor cell apoptosis via the Fas–nuclear factor-kappa B 
(NF-kB) and caspase families.9,10 Furthermore, increased 
PEDF has been observed in the peripheral blood of patients 
with obesity or atherosclerosis.11,12 Finally, a previous study 
has demonstrated PEDF-induced inflammatory signaling in 
muscle and fat cells.13 However, whether PEDF is involved 
in the pathogenesis of COPD is unknown.
The aim of the present research was to explore the 
potential role of PEDF in COPD. In the present study, we 
measured PEDF expression in both cigarette smoke extract 
(CSE)-stimulated epithelial cells and lung tissues of rats 
exposed to cigarette smoke (CS). We also detected the plasma 
concentration of PEDF and classic proinflammatory cyto-
kines in nonsmoker (NS) controls, healthy smokers (HS), and 
stable COPD patients. In addition, we performed a spirometry 
examination and analyzed the correlations between PEDF 
and lung function in the study subjects. Our findings provided 
a novel link between PEDF and COPD, suggesting that PEDF 
is involved in the pathogenesis of COPD.
Methods
Cell culture
Human lung cells (NCI-H292) were purchased from the 
American Type Culture Collection (Manassas, VA, USA). 
Cells were cultured at 37°C in a 5% CO
2
 environment
 
in 
Roswell Park Memorial Institute (RPMI)-1640 medium 
(Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10% fetal bovine serum (FBS) (Invitro-
gen; Thermo Fisher Scientific) and 100 U/mL of penicillin 
and streptomycin antibiotics (penicillin–streptomycin, Invit-
rogen; Thermo Fisher Scientific). CSE in RPMI medium 
was freshly prepared for each experiment, as previously 
described.14
animals
Male specific pathogen-free grade Sprague Dawley rats 
(weighing 180–220 g) were obtained from the Laboratory 
Animal Center of Sichuan University (Chengdu, People’s 
Republic of China). Animals had free access to regular 
food and tap water, and they were maintained on a 12-hour 
light/12-hour dark cycle at a room temperature of 23°C±2°C. 
All rat experiments were performed according to the Labo-
ratory Animal Care Guidelines of West China School of 
Medicine, Sichuan University.
Patient population
Eighty subjects aged from 40 to 90 years were recruited from 
September 2012 until August 2013 in Sichuan Province, 
People’s Republic of China. We collected questionnaires 
and performed physical examinations to obtain the subjects’ 
background information. We also performed diagnostic tests, 
including pulmonary function tests, using a Spirotel® spiro-
meter purchased from Mir Medical International Research 
Srl (Rome, Italy) and chest X-ray to screen COPD patients. 
Twenty nonsmoking volunteers with normal spirometry 
results and without a history of cigarette smoking were 
included as the healthy NS group. Ten smoking volunteers 
with normal spirometry results and a tobacco smoking his-
tory were considered as the HS group. According to the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) classifications, subjects with postbronchodilator 
forced expiratory volume in 1 second (FEV
1
)/forced vital 
capacity (FVC) ,70% were enrolled as the COPD patient 
group. All subjects taking glucocorticoids (inhaled and 
oral) and bronchodilators in the previous 3 months were 
excluded. In addition, participants with respiratory disorders 
(bronchiectasis, lung cancer, tuberculosis, and chronic bron-
chitis) or diseases known to be associated with an increase 
in circulating PEDF (retinopathy) were not enrolled. Our 
study was approved by the Ethics Committees at the West 
China School of Medicine, Sichuan University. All subjects 
provided their signed informed consent.
Measurements of circulating PeDF 
and blood parameters
We drew the venous peripheral blood of subjects, and the 
samples were then centrifuged for 10 minutes at 400 g at 4°C. 
The plasma was collected and stored at -80°C until measure-
ment. Concentrations of PEDF, C-reactive protein (CRP), inter-
leukin (IL)-8, IL-6, and tumor necrosis factor (TNF)-α were 
determined using Milliplex MAP circulating enzyme-linked 
immunosorbent assay (ELISA) kits according to the manufac-
turer’s protocol (Merck KGaA, Darmstadt, Germany).
Blood samples were detected by an SF-3000 blood coun-
ter system, and white blood cells were categorized. Blood 
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glucose levels and cholesterol levels were measured via a 
biochemistry method.
stable isotope labeling with amino acids 
in cell culture
Briefly, H292 cells were labeled with a stable isotope when 
confluence reached approximately 70%. The cells were then 
starved with FBS and free RPMI medium and incubated 
with or without CSE for 24 hours. Afterwards, the cells 
were harvested and the differences in expressing proteins 
were detected using mass spectrometry-based quantitative 
proteomics.
exposure of rats to Cs
Cigarettes were purchased from the Cigarette Factory and 
contained 1.0 mg of nicotine and 14 mg of tar per cigarette 
(Tianxiaxiu, Chengdu, People’s Republic of China). Animals 
were handled and exposed to CS, as previously described.15 
Briefly, wild-type rats were subsequently exposed to CS (five 
cigarettes) for 30 minutes twice a day, 6 days per week, and 
for up to 4 weeks using a mechanical smoking chamber. 
Sham rats were exposed to ambient air as control. After 
4 weeks of CS exposure, the rats were sacrificed and lung 
tissues were collected for Western blotting.
Western blotting analysis
The lung tissues of the sham and CS rat groups were homo-
genized with radioimmunoprecipitation assay (RIPA) lysis 
buffer supplemented with a protease inhibitor cocktail and 
phenylmethylsulfonyl fluoride (PMSF) (Biocolor BioScience 
Technology Company, Shanghai, People’s Republic of 
China). The lysates were centrifuged at 12,000 rpm for 
30 minutes at 4°C, and the supernatants were subsequently 
collected. Concentrations of the total protein were mea-
sured by the BCA protein assay kit (Pierce Biotechnology, 
Rockford, IL, USA). The procedure was performed as previ-
ously described.16 Equal amounts of protein were immuno-
blotted with anti-PEDF primary antibody. The density of the 
bands was quantified using ImageJ software and normalized 
against anti-β-actin an as a control.
statistical analysis
Values were presented as the mean ± standard error, unless 
otherwise indicated. All statistical analyses were conducted 
using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). The 
normal distribution of these data has been confirmed. For 
multiple comparisons, one-way analysis of variance and least 
significant difference were used to analyze the experimental 
data. Pearson’s correlation analysis was used to investigate 
the correlations between the PEDF levels and inflamma-
tory cytokine or lung function parameters. The association 
between patient characteristics and PEDF levels was evalu-
ated by multivariate linear regression analysis. P#0.05 was 
considered statistically significant.
Results
elevated PeDF levels in Cse-treated 
pulmonary epithelial cells and in the lung 
homogenate of rats exposed to Cs
To investigate the candidate proteins involved in the patho-
genesis of COPD, we stimulated the pulmonary epithelial 
cells with CSE. As described in the Methods section, we 
cultured the human pulmonary epithelium NCI-H292 cell 
line with/without CSE treatment for 24 hours. Afterwards, 
the protein expression changes of the samples were identified 
using a mass spectrometer. We found that CSE dramatically 
induced PEDF secretion as much as 16.2-fold more than in 
the untreated cells (Figure 1A). To further confirm this obser-
vation, we also collected the lung tissues of rats that were 
exposed to CS for 4 weeks, and we detected PEDF expression 
in lung homogenate by Western blotting. It was found that 
the PEDF protein consistently increased more than twofold 
in the CS-treated mice when compared with the mice in the 
sham group (Figure 1B). Considering that cigarette smoking 
is the most common cause of COPD, our data indicate that 
PEDF may be involved in sustained inflammation, which is 
induced by cigarette smoking in COPD.
Clinical characteristics of COPD patients
To examine whether PEDF is a potential mediator in COPD 
pathogenesis, we measured the circulating PEDF levels in 
recruited healthy participants with or without a history of 
smoking and also in stable COPD patients. The general clini-
cal characteristics of the healthy volunteers with or without a 
history of smoking, as well as the COPD patients, are shown 
in Table 1. Subjects in the NS, HS, and COPD groups were 
age matched, and there were no differences in body mass 
index, blood pressure, and metabolism parameters. The HS 
group had more male subjects than did the NS group, but 
not more than the COPD group. COPD patients had a lower 
PaO
2
 level when compared with the NS subjects. In addition, 
HS had a higher, though not significant, mean cumulative 
tobacco consumption of 33.00±5.37 packs/year, as compared 
with the COPD patients, who had a mean tobacco consump-
tion of 21.48±2.46 packs/year.
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Figure 1 Cigarette smoke (Cs)-induced pigment epithelium-derived factor (PeDF) expression both in vitro and in vivo. 
Notes: (A) human h292 cell lines were cultured and labeled with a stable isotope. Cells were incubated with or without the presence of cigarette smoke extract (Cse) for 
24 hours. Then, cells were harvested to measure molecular species compositions of the cell protein using mass spectra. CSE significantly induced PEDF protein expression 
as much as 16.2-fold when compared with untreated controls. The experiment was repeated three times and a representative result is shown here. (B) Wild-type rats were 
exposed to Cs for 4 weeks (2×30 minutes/day and 6 days/week) using a mechanical smoking chamber. sham rats were exposed to ambient air as control. afterwards, rat 
lung tissues were homogenized to extract protein. Samples were detected using Western Blotting with specific PEDF and β-actin antibodies. Band densities were quantified 
and bars showed fold changes normalized to β-actin as control. Each group included five rats and the experiment was repeated three times.
Table 1 Characteristics of healthy volunteers and COPD patients in stable condition
NS (n=20) HS (n=10) COPD (n=50) P-value
age, years 60.25±1.62 60.70±1.23 63.78±1.37 0.242
sex, male % 50 100§ 72 0.016
Body mass index, kg/m2 23.54±0.64 24.46±1.08 23.65±0.48 0.739
Physiological parameters
systolic blood pressure, mmhg 145.05±5.02 129.90±4.88 137.35±2.88 0.137
Diastolic blood pressure, mmhg 86.95±2.98 78.70±2.99 80.65±1.68 0.094
PaO2, mmhg 98.55±0.14 98.10±0.35 97.21±0.34* 0.028
risk factors
Pack-years smoking index 0 33.00±5.37§ 21.48±2.46* 0.073
Metabolism parameters
Total cholesterol, mg/dl 4.94±0.19 4.59±0.30 4.92±0.14 0.556
Fasting glucose, mg/dl 6.18±0.78 5.68±0.46 5.36±0.09 0.273
Notes: Values are presented as the means ± standard error, unless otherwise indicated. The normal distribution of the data has been checked. analysis of variance was used 
to analyze the difference between groups and followed by least significant difference test to compare any of the two groups. *Represents significance for COPD versus NS; 
§for hs versus ns. Bold denotes a value of P,0.05, which was considered to be statistically significant.
Abbreviations: COPD, chronic obstructive pulmonary disease; ns, healthy nonsmokers; hs, healthy smokers.
Circulating PeDF is upregulated  
in COPD patients
We then measured the PEDF levels using multiplex ELISA. 
We found that PEDF levels had increased significantly in the 
plasma of COPD patients in comparison with both the NS and 
HS groups (551.16±23.66 versus 378.80±27.92 ng/ml; and 
551.16±23.66 versus 439.80±51.78 ng/ml, respectively; 
 Figure 2). There were no differences found among the healthy 
volunteers (Figure 2).
PeDF may play a role in mediating the 
proinflammatory response in COPD
Next, we investigated the relationship between PEDF and 
COPD inflammatory mediators. In our study, selected 
inflammation biomarkers, including CRP, IL-8, TNF-α, and 
IL-6 levels in peripheral blood, were distinguished among 
the COPD patients, the NS group, and the HS group. In the 
univariate analysis, there were positive correlations between 
PEDF and CRP (r=0.4294; P,0.0001), IL-8 (r=0.2947; 
P,0.008), TNF-α (r=0.2665; P,0.0169), and IL-6 
(r=0.3433; P,0.0018). Since neutrophils were reported to 
be responsible for lung destruction and chronic inflammatory 
processes, we then analyzed the correlation between PEDF 
expression and neutrophil count via whole blood analysis. 
As shown in Figure 3E–F, PEDF levels were positively 
correlated with neutrophil count and percentage (r=0.3086, 
P,0.0054; and r=0.2202, P=0.0497, respectively). We 
also performed a univariate analysis on the PEDF levels in 
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Figure 2 levels of pigment epithelium-derived factor (PeDF) in the plasma from 
the healthy nonsmokers group, healthy smokers group, and chronic obstructive 
pulmonary disease (COPD) group. Circulating PeDF concentrations were measured 
using multiplex enzyme-linked immunosorbent assay. COPD patients had a signifi-
cantly elevated PeDF level when compared with those of the healthy nonsmoker and 
smoking subjects (P=0.0001 and P=0.0477, respectively). There was no difference 
between the healthy nonsmokers and smokers (P=0.2712). The expression of PeDF 
is presented as the median (interquartile range) and compared by one-way analysis of 
variance. a value of P,0.05 was considered to be statistically significant.
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Figure 3 Circulating pigment epithelium-derived factor (PeDF) levels were correlated with established chronic obstructive pulmonary disease (COPD) biomarkers. PeDF 
concentration was positively correlated with (A) serum C-reactive protein (CrP) (r=0.4294; P,0.0001); (B) interleukin (Il)-8 (r=0.2947; P=0.0080); (C) tumor necrosis 
factor (TnF)-α (r=0.2665; P=0.0169); and (D) Il-6 (r=0.3433; P=0.018). (E, F) The absolute value of PeDF was also correlated with either neutrophil number or neutrophil 
percentage (r=0.3086, P=0.0054; r=0.2202, P=0.0497, respectively). The solid line denotes the line of best fit, and Pearson’s correlation coefficient is presented as an 
r-value.
association with the subjects’ age, sex, and smoking pack-
years, which were not related (data not shown).
PeDF is reversely correlated with lung 
function
Table 2 shows the spirometry results of the healthy volunteers 
and COPD patients. Inverse correlations between PEDF and 
FEV
1
 percent predicted (r=-0.3303, P=0.0028; Figure 4A) 
and FEV
1
/FVC (r=-0.3116, P=0.0049; Figure 3B) were 
observed.
Multivariate linear regression analysis
Finally, we evaluated the interaction of the aforementioned 
parameters on changes in PEDF levels across all subjects 
using multivariate linear regression analysis. As shown in 
Table 3, CRP and IL-6 were the independent parameters 
associated with PEDF.
Discussion
In the present study, we found that CSE can induce levels 
of PEDF that are 16 times greater than those in the control 
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Table 2 spirometry results of healthy volunteers and COPD patients in stable condition
Lung function NS (n=20) HS (n=10) COPD (n=50) P-value
FeV1, l 2.71±0.16 2.79±0.15 1.67±0.09*,# ,0.0001
FVC, l 3.47±0.19 3.59±0.17 3.21±0.12 0.27
FeV1/FVC ratio 84.75±1.03 82.03±1.00 54.06±1.75*,# ,0.0001
FeV1% pred 118.80±3.77 107.80±3.58 70.28±2.42*,# ,0.0001
VC max 3.40±0.20 3.58±0.19 3.27±0.13 0.55
IC 2.33±0.11 2.31±0.20 2.21±0.10 0.75
MMeF 75/25 2.74±0.25 2.41±0.22 0.72±0.08*,# ,0.0001
PeF 7.04±0.49 7.19±0.37 4.00±0.29*,# ,0.0001
FeF25 6.43±0.44 6.51±0.28 2.26±0.22*,# ,0.0001
FeF50 4.07±0.31 3.74±0.37 0.92±0.09*,# ,0.0001
FeF75 1.21±0.10 1.09±0.12 0.28±0.03*,# ,0.0001
Notes: Values are presented as the means ± standard error, unless otherwise stated. analysis of variance was used to analyze the difference between groups and was 
followed by the least significant difference test to compare any of the two groups. *Represents significance for COPD versus NS; #for COPD versus hs. Bold denotes a value 
of P,0.05 that was considered to be statistically significant.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FeV1/FVC, ratio of FeV1 to FVC; FeV1% pred, FeV1 percent predicted; VC max, vital 
capacity; IC, inspiratory capacity; MMEF 75/25, maximum mid-expiratory flow; PEF, peak expiratory flow; FEF25, forced inspiratory flow 25%; FEF50, forced inspiratory flow 
50%; FEF75, forced inspiratory flow 75%; COPD, chronic obstructive pulmonary disease; NS, healthy nonsmokers; HS, healthy smokers.
Figure 4 Correlation analysis between PeDF levels and pulmonary function. 
Notes: (A) PeDF in the plasma was negatively correlated with FeV1% predicted (r=-0.3303; P=0.0028). (B) a similar correlation was observed between PeDF and FeV1/FVC 
(r=-0.3116; P=0.0049). The solid line denotes the line of best fit. Pearson’s correlation coefficient is presented as an r-value.
Abbreviations: PeDF, pigment epithelium-derived factor; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; COPD, chronic obstructive pulmonary 
disease.
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groups in cultured epithelial cells. Correspondingly, PEDF 
expression in rat lungs was upregulated twofold by exposure 
to CS. These results captured our attention, and we proposed 
that PEDF may participate in the development of COPD. We 
then compared the circulating PEDF concentrations in COPD 
patients in a stable condition with those of their counterpart 
controls. We first demonstrated that plasma PEDF levels in 
COPD patients were significantly higher than those in either 
the healthy nonsmoking or smoking subjects. Furthermore, 
PEDF was correlated with the presence of classic inflamma-
tory biomarkers in systemic COPD. We also found correla-
tions between PEDF levels and lung function decline. Our 
results indicated the potential relationship between increased 
PEDF levels and the inflammation involved in COPD, which 
implies that PEDF may participate in the pathogenesis of 
COPD.
The identification of PEDF as a proinflammatory factor is 
reported in several recent studies.5,13,17 Chavan et al5 observed 
that the culture medium of 3T3-L1 adipocytes significantly 
activated macrophages to produce TNF. PEDF was identified 
as the exact molecule involved in adipocyte-secreted proteins, 
which regulate macrophages via the PEDF receptor, ATGL/
iPLA2. In accordance with the positive correlation found 
between PEDF and proinflammatory cytokines in our study, 
it was reported that exogenous PEDF activated the expression 
of TNF, IL-1, and IL-6 in a dose-dependent manner. Notably, 
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These interesting findings showed the possibility that 
PEDF-induced apoptosis may also contribute to the loss of 
pulmonary parenchyma in COPD.
We first identified that PEDF was increased in the cir-
culation of COPD patients. The findings of our preliminary 
research showed the possibility that PEDF could contribute 
to chronic inflammatory responses in the development of 
COPD. Although there was an increase in the levels in COPD 
patients as a group, PEDF does not seem to be significantly 
related to COPD severity. These results might be influenced 
by several factors. First, whether the destruction of lung 
parenchyma contributes to the expression of PEDF levels is 
unclear. Second, the elevation of systemic mediator expres-
sion is generally considered to be the outcome of a “spill-out” 
of PEDF from the lungs of COPD patients; however, compli-
cations may also increase PEDF concentrations in circulation. 
To confirm this hypothesis, we need to conduct more research 
on the PEDF levels in the bronchoalveolar lavage fluid of 
COPD patients and obtain pathological evidence from lung 
tissues. Another explanation for these results is that we did 
not have a high enough number of severe COPD patients, and 
this may have had some influence on the relationship between 
PEDF levels and COPD severity. Therefore, it is necessary to 
recruit more stage III and stage IV COPD patients in subse-
quent studies. A lack of information regarding the molecular 
mechanisms that regulate PEDF in COPD patients also limits 
our understanding of the role of this multifunctional protein, 
which also needs further study.
In conclusion, we first identified that PEDF was induced 
in either CSE-treated pulmonary epithelial cells or rat lung 
tissues exposed to CS. Accordingly, we also found that 
elevated PEDF levels in circulation may be related to the 
inflammatory response in COPD, and that this can be cor-
related with the decline in lung function in these patients. 
Our findings reveal the potential correlation that PEDF may 
participate in the inflammation involved in COPD.
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age -0.071 0.51
sex 0.011 0.91
BMI 0.046 0.65
Pack-years 0.002 0.99
Il-6 0.28 0.01
Il-8 0.115 0.29
TnF-α 0.108 0.310
CrP 0.34 ,0.0001
FeV1/FVC -0.122 0.26
FeV1% pred -0.188 0.080
Notes: The value of β represents standard regression coefficient. Bold denotes a 
value of P,0.05.
Abbreviations: PeDF, pigment epithelium-derived factor; COPD, chronic 
obstructive pulmonary disease; BMI, body mass index; Il, interleukin; TnF, tumor 
necrosis factor; CrP, C-reactive protein; FeV1, forced expiratory volume in 1 
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PEDF performed a potent function in regulating multiple 
inflammatory signaling. The treatment of recombinant PEDF 
directly induced p38 mitogen-activated protein kinase (p38 
MAPK) and extracellular signal regulated kinase (ERK)1 and 
ERK2.13 In COPD, p38 MAPK and ERK1/2 were revealed 
to be activated in lung structure and inflammatory cells, 
strengthening inflammatory responses and weakening steroid 
responses.18,19 Moreover, NF-kB plays an essential role in 
COPD to induce the enhancement of multiple inflammatory 
genes.20 In human vascular smooth muscle cells, PEDF can 
acutely activate the NF-kB signaling pathway, as well as 
initiate mTOR and AKT signaling.13 Therefore, the eleva-
tion of PEDF levels in COPD patients may play a role in the 
pathogenesis of COPD by mediating multiple inflammatory 
signaling processes.
Apoptosis is newly observed in COPD patients and 
contributes to a loss of pulmonary parenchyma.21,22 The 
proapoptotic property of cellular PEDF is comprehensively 
discussed. Recent studies have reported that PEDF partici-
pated in regulating classic apoptosis pathways, including the 
PEDF–Fas/FasL and PEDF–NF–kB–caspase 8 pathways.9,23 
Moreover, our unpublished data showed that PEDF was 
closely correlated with levels of mitochondrial deoxyribo-
nucleic acid, which can be released into the extracellular 
space from apoptotic cells. Suzuki et al24 found decreased 
levels of vascular endothelial growth factor (VEGF) and 
vascular endothelial growth factor receptor (VEGFR) I 
in the bronchoalveolar lavage fluid, induced sputum, and 
serum of COPD patients. The overexpression of PEDF 
also induced cell death by inhibiting the phosphorylation of 
VEGF and VEGFR I, leading to the caspase-3 cascade.25,26 
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